Angiotensinogen (AGT) gene polymorphism has shown significant differences in the allelic frequencies between hypertensive and normotensive subjects. This allele frequency varies among ethnic groups. There are still some controversies related to the 235T-variant as a marker for essential hypertension. As part of an extensive case-control study carried out in a Spanish population, we selected the 237 subjects with a diagnosis of essential hypertension according to the established criteria. A group of 242 normotensives matched for age and gender was used as control. Smoking habits, a previous diabetes and hypertension medical history, body mass index (BMI) and blood pressure (BP) values were recorded. Glucose, plasma creatinine, lipid profile with Lp(a), homocysteine and microalbuminuria were measured. Angiotensinogen M235T-gene polymorphism was
Introduction
Arterial hypertension (AH) is a known risk factor that contributes to the morbidity and mortality by cardiovascular causes 1 affecting approximately 25% of the adult population in Western countries. Numerous family and biometric studies have confirmed a genetic component in the susceptibility to the development of essential hypertension under certain environmental conditions. 2 The substitution polymorphisms M235T and T174M located at the angiotensinogen (AGT) gene classified by Jeunemaitre et al 3 showed significant differences in the allelic frequencies between hypertensive and normotensive subjects. The 235T allele has been associated with higher plasma concentrations of AGT, about 15-40% higher in 235T homozygous compared with M235 homozygous determined by polymerase chain reaction (PCR) from genomic DNA. A(-6)G polymorphism was determined by mutagenically separated PCR (MS-PCR). BP values, BMI and microalbuminuria were significantly higher in hypertensive subjects; 31.6% of hypertensives and 40.1% normotensives were active smokers. M235T-genotype frequencies were not different in the hypertensive and normotensive population. Similarly, homocigotic AA predominate in the hypertensives but without statistical significance. The association of 235T-genotype or the changes in the promoter activity due to A(-6) substitution with essential hypertension was not confirmed in the multivariate regression analyses. Only a previous family history of hypertension and BMI were significantly associated with hypertension. Journal of Human Hypertension (2000) 14, 789-793 individuals. [3] [4] [5] It has been observed that the 235T allele frequency differs among different ethnic groups studied. In the white population it varies from 0.35 to 0.45, 3, [6] [7] [8] [9] while in the Japanese the range increases from 0.6-0.75. [10] [11] [12] The highest prevalence of this allele is found among Africans, where it varies from 0.84 to 0.93. 10, 13, 14 However, the exact role of the M235T polymorphism as a marker for AH is still a subject of controversy. Through case-control studies, the Threonine allele (235T) of M235T have been associated with elevated risk of hypertension, 3, 8, 10, 11, 15 in some populations, but not in others. 6, 13, [16] [17] [18] [19] The M235T polymorphism has been shown to be in very tight linkage disequilibrium with a variation known as A(-6)G. This involves a swap of adenine to guanine six nucleotides upstream from the site of transcription initiation in the AGT promoter. 20, 21 Although M235T polymorphism is associated with plasma angiotensinogen level variation it does not seem to have a functional role; however A(-6) is known to affect the basal rate of the AGT gene transcription. The 235T associations described may only reflect changes in the promoter activity through an A(-6) substitution. 1, 21 In this study we investigated:
Journal of Human Hypertension (a) a possible relationship between the AGT M235T and AGT A(-6)G gene polymorphisms and AH in a sample of hypertensive subjects, to define the role of these gene variants as markers for AH, and (b) whether these genotypes are associated with other classic risk factors for hypertension.
Materials and methods

Patients and controls
All of the individuals studied were previous participants in the Prospective Cardiac Gene Study (PROCAGENE), a case-control carried out in Gran Canaria (Canary Islands, Spain) between January, 1996 and December, 1998 to investigate the association between renin-angiotensin system (RAS) genes and coronary heart disease assessed by coronary angiography. 22 A total of 867 Caucasian subjects were recruited. Male and female adults were at least 18 years old with an upper age limit of 79 years. We required that all the subjects were born in the Canaries to Canarian parents or resident in the islands for more than 10 years and of Spanish parents. All of them responded to a questionnaire on medical history and personal habits. Several blood samples were obtained after 12-h fasting for biochemical and DNA studies. The controls sample design was sampled at random in the study period and cluster stratified based on a population census. Controls were characterised because neither presented cardiovascular nor stroke events. Cases were recruited from a group admitted to Gran Canaria hospitals for treatment of myocardial infarction or unstable angina. We selected 237 individuals from the PROCAGENE participants, who had been diagnosed with primary hypertension according to the following criteria: (1) previous diagnosis of hypertension and receiving antihypertensive medication, (2) if they had diastolic blood pressure (DBP) Ͼ90 mm Hg and/or systolic BP (SBP) Ͼ140 mm Hg when examined, and (3) did not present secondary forms of hypertension. All participants were interviewed concerning birthplace, smoking habits, previous history of physician-diagnosed hypertension, physical activity, medication, hyperlipidaemia, alcohol consumption, diabetes mellitus and oral contraceptives and hormonal substitutive therapy in women. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. BP was measured in the right arm after subjects had voided, had not smoked for 15 min, and had rested for 5 min in decubitus position. Trained nursing staff recorded BP values using a semiautomatic manometer Omron Hem 705CP calibrated in accordance with British Society of Hypertension protocol. 23 Triplicate measurements were taken on the same arm, waiting at least 30 s between readings. We also selected 242 normotensive subjects matched for age and gender. All had DBP р90 mm Hg and SBP р140 mm Hg and had never been treated with antihypertensive medication. All the selected individuals gave their consent to participate in the study after being given appropriate information. The protocol was approved by the Ethics Committee of the Hospital de Gran Canaria Dr. Negrín.
Biochemical measurements and genetic determinations
One blood sample was tested for levels of plasma glucose, serum creatinine, total cholesterol, HDLcholesterol and triglycerides with the use of enzymatic-colorimetric methods. Lipoprotein (a) (Lp (a)) was analysed using an immunoturbidimetric method (Boehringer Mannheim, Germany). Homocysteine assay is based on the Fluorescense Polarization Immunoassay (FPIA) technology (Abbott Diagnostic Division, UK). Microalbuminuria was measured by an immunoturbidimetric assay (Boehringer Mannheim).
DNA was extracted from leukocytes by salting out, 24 stored at 4°C and used for all genetic determinations (one control subject was not genotyped because of an insufficient sample). The AGT M235T polymorphism was typed by the mismatch method previously described 16, 25 with some modifications. Primers used were:
Agt1: 5Ј GAT GCG CAC AAG GTC CTG TC 3Ј Agt2: 5Ј CAG GGT GCT GTC CAC ACT GGC TCG C 3Ј
Genomic DNA was amplified in a PTC-100 thermal cycler. Ten microliters of the amplified product were digested overnight at 37°C with 0.3 units of SfaNI (New England Biolabs, Beverly, MA, USA). Products were visualised by ethidium bromide staining after electrophoretic fractionation through 3.5% agarose gels. The AGT-A(-6)G polymorphism was determined by mutagenically separated PCR (MS-PCR) as has been described by Morgan et al, 20 with minor modifications. Three primers were used: Agt-6MS5: 5Ј GTG TCG CTT CTG GCA TCT GTC CTT CTG G 3Ј as a common forward primer. Agt-6MS3ЈS: 5Ј TAC CCA GAA CAA CGG CAG CTT CTT CCA CT 3Ј for the detection of allele A(-6). Agt-6MS3ЈL: 5Ј CCG GTT ACC TTC TGC TGT AGA GCC CAG AAC AAC GGC AGC TTC TTC CAT C 3Ј for the detection of allele G(-6).
Amplification was carried out in the presence of 2 pmol of Agt-6MS5Ј, 4 pmol of Agt-6MS3ЈS and 8 pmol of Agt-6MS3ЈL. Products, a 187 bp for A(-6) allele and a 212 bp for G(-6) allele, were fractionated through 3% agarose plus 1% High Efficiency Separation agarose (Amersham Life Science, Aylesbury, UK).
Statistical analysis
The SPSS statistical software package, version 8.0 for Windows was used for data analysis. P Ͻ 0.05 was considered to indicate statistical significance. A 2 test assessed the fit of the observed alleles frequencies to Hardy-Weinberg equilibrium. The differences in genotype and allele frequencies between cases and controls were tested using 2 analysis. Continuous variables are expressed as mean ± s.d. according to clinical features and the differences among groups were compared using the unpaired Student's t-test. An ANOVA test was used, and the differences between individuals classified by genotype were compared with Bonferroni correction for multiple comparisons. Multiple regression analysis was also performed with AH (presence or absence) as the dependent variable, and age, sex, BMI (categorised as BMI Ͻ26 or BMI у26), smoking status, previous family history of arterial hypertension and genotypes as independent variables. Genotypes M235T and A(-6)G were introduced separately.
We
The same approach was used with A(-6)G genotypes AA, AG and GG respectively.
Results
The characteristics of the hypertensive subjects and the normotensive controls are shown in Table 1 . The 237 hypertensive subjects (171 male and 66 female) did not differ significantly in age from the 242 control normotensives (183 male and 59 female). We did not detect significant differences in the mean concentration of total cholesterol, cholesterol-LDL, cholesterol-HDL, Lp(a) and triglycerides. Both SBP and DBP showed significant differences between the hypertensive group (148 ± 26 and 86 ± 14 mm Hg) and the normotensive control group (131 ± 21 and 76 ± 11 mm Hg). Among the first, hypertensive subjects under medication were included as well as those with normalised pressure levels. The BMI was significantly raised (t = 4.901, P = 0.0001) among hypertensive subjects compared to normotensive 
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ones (28 ± 4 vs 27 ± 3). Microalbuminuria was also significantly higher among hypertensive subjects (t = 3.015, P = 0.003). Seventy-five hypertensive subjects were smokers (31.6%) without differences compared to the 97 (40.1%) normotensive smokers ( 2 = 3,704, 1df; P = 0,054).
Some studies indicate that mean concentration of homocysteine is raised in AH. 26, 27 In our study, mean plasma concentration of homocysteine was raised in the hypertensive group compared to the normotensive one although the difference was not statistically significant. When we distributed the subjects by sex, homocysteine infer a trend to significant difference (t = 1.950; P = 0,05) between the male group with AH (16.98 ± 7.4) and the normotensive males (15.61 ± 5.59).
Distribution by genotypes M235T and A(-6)G are presented in Table 2 . We did not find any differences in the frequencies of the genotypes compared to those of the Hardy-Weinberg expectations in the total population studied as in the case and control groups. When we compared the groups we found that the frequency of 235T homozygotes was greater in the hypertensive group (n = 57, 24.1% vs n = 54, 22.49%) although there was no detectable statistical difference ( 2 = 1.082, 2df; P = 0.582). Similarly, homozygotes with AA genotype of the polymorphism A(-6)G were more prevalent in the hypertensives compared to the normotense controls (n = 60, 25.4% vs n = 56, 23.2%) but also without statistical significance. The genotype and allele frequency was compared in the hypertensives and normotensives stratified by sex. A greater proportion of homozygotes 235T and A(-6) was observed amongst hypertensive cases, but this was not significant. However, difference of TT plus MT combined genotypes between hypertensive subjects and normotensive controls, was proportionally higher in women (hypertensives: 80.3% vs normotensives: 66.1%) than among men (74.3% vs 73.6%). The same results were observed when compared frequency distribution of AA plus AG genotypes between hypertensives and normotensives distributed by sex. Pairwise comparisons did not shown significantly differences on continuous variables according to each AGT genotype (P Ͼ 0.05, Bonferroni t-test).
Therefore we did not confirm previous observations that the 235T or A(-6) variants of the AGT gene are associated with hypertension. In addition, only previous familial history of hypertension and BMI were significantly associated with hypertension in all multivariate models.
Discussion
Genetic approaches to complex diseases have been recently reviewed. 28 Potential confounders include problems with sample size, ethnicity, publication bias toward positive results, and inaccurate definition of disease phenotypes. The genes that encode proteins of the renin-angiotensin-aldosterone (RAA) system crucial in the regulation of blood pressure, have been proposed as candidates for AH development. In 1992, Jeunemaitre et al, 3 reported linkage of the AGT locus to AH, using a marker located in 29 developed a genetic linkage study by the affected sib-pair method using two different statistical methods that also differ from those described by Jeunemaitre et al. 3 This work did not show evidence of linkage of the AGT gene and AH. These findings stress the necessity of considering ethnic factors in the assessment of genetic risk identifiers. Also Wang et al, 19 have reported controversial results with AGT gene in a hypertensive Australian population.
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The association between 235T allele and AH has been described epidemiologically in the Caucasian population, 30 in the Japanese 31, 32 and in native Canadians. 33 An absence of association has been observed in Africans, 14, 16 in Chinese 34, 35 and in the Australian population. 19 In the meta-analysis of Kunz et al, 10 which includes 5493 patients, carried out in a white population, the estimated associated risk to the allele 235T was 1.2 (95% Cl, 1.11 to 1.29; P Ͻ 0.0001). The risk increased when we considered the family history of AH or the AH was stratified, but different bias were also reported in the studies analysed which reflected, for example, defects in their selection of the sample size or lack of homogeneity in the population studied. In the metaanalysis of Kato et al, 15 carried out in the Japanese population, no significant association was found between polymorphism M235T and AH.
In a recent paper, Ishigami et al 36 show an association between variant A(-20)C in the AGT gene promoter region and the variations in the plasma concentration of angiotensinogen, whereas A(-6)G and T+68C were associated with higher values of DBP and SBP. In addition, Fardella et al 37 found a correlation between plasma and urine levels of aldosterone with genotypes A(-6)G. The A allele was associated with raised aldosterone levels, suggesting that a greater transcriptional activity of the gene AGT implies increased production of aldosterone.
In our study, A(-6)G and M235T are not associated with raised DBP or SBP values which may be attributable to our decision to include hypertensives under drug treatment. Although we have detected slightly increased frequencies of 235T and A(-6) alleles in the hypertensive population, it was not significant (␤ error of 0.07). However, we cannot exclude that M235T and A(-6)G polymorphism could be related with some model of arterial hypertension. In this sense, a major reduction of SBP by decreasing sodium intake in those hypertensives with 235T allele, has been observed. 38 The multifactorial nature of hypertension may mean that other genes are more important in this population.
We found that M235T and A(-6)G polymorphisms are in strong linkage disequilibrium which agrees with the published literature. 21 In this respect 235T and A(-6) alleles represent ancestral forms of the AGT gene which may have afforded evolutionary advantage in diets which are low in sodium. In a recent review, Corvol et al, 39 reported limitations of association and linkage studies in hypertensive aetiology. Among the factors which highlight statistical limitations are the genetic variability between study populations and the phenotypic characteristic of hypertensive subjects. 39 In summary, we have not demonstrated relationships of 235T and A(-6) alleles of the AGT gene polymorphisms with arterial hypertension in our population. Since family studies suggest that only 30% of the variation in BP are genetically determined 2 the effect of a single gene may be small and difficult to detect. In support of this suggestion Jeunemaitre et al, 3 showed that M235T only contributed between 3 and 6% of the cases with essential AH developed before 60 years of age.
